Loading…
Organon & Co. is projected to rise to $14.51 by 2027, a +8% move from its current price of $13.38. OGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $13.04 | $13.38 | $13.73 | +0.03% |
| May 30 | $12.91 | $13.39 | $13.88 | +0.05% |
| May 31 | $12.80 | $13.39 | $14.00 | +0.08% |
| Jun 1 | $12.72 | $13.39 | $14.10 | +0.10% |
| Jun 2 | $12.65 | $13.40 | $14.19 | +0.13% |
| Jun 3 | $12.58 | $13.40 | $14.28 | +0.15% |
| Jun 4 | $12.52 | $13.40 | $14.35 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $12.52 | $13.40 | $14.35 | +0.18% |
| Week 2 | $12.19 | $13.43 | $14.79 | +0.36% |
| Week 3 | $11.95 | $13.45 | $15.14 | +0.54% |
| Week 4 | $11.75 | $13.48 | $15.45 | +0.72% |
| Week 5 | $11.59 | $13.50 | $15.73 | +0.90% |
| Week 6 | $11.44 | $13.52 | $15.99 | +1.08% |
| Week 7 | $11.31 | $13.55 | $16.23 | +1.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Organon & Co. is a healthcare company that develops and delivers women’s health solutions through prescription therapies and medical devices across the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss.
Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Organon & Co. (OGN) is a healthcare stock currently priced at $13.43, with a market cap of $3.53B and a rank of 1605.
The near-term forecast for 2026 shows a min of $5.70, an avg of $13.43, and a max of $17.13, with a neutral sentiment and ROI of 0.
Looking further, the forecast envisions a bullish trajectory with 2027 avg $14.65, 2028 avg $16.42, 2029 avg $16.92, 2030 avg $20.42, 2040 avg $46.83, and 2050 avg $77.73, along with rising ROIs and a bullish overall outlook.
A major floor 57.4% below — a decisive break under it would weaken the trend.
The nearest floor, 35.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.6% away) — a breakout level to watch.
A major ceiling 24.6% above — clearing it would confirm fresh momentum.
Key OGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of OGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $13.42 | Sell | $13.40 | Sell |
| MA 10 | $13.40 | Sell | $13.35 | Buy |
| MA 20 | $13.36 | Buy | $12.82 | Buy |
| MA 50 | $9.99 | Buy | $11.01 | Buy |
| MA 100 | $8.92 | Buy | $9.75 | Buy |
| MA 200 | $8.77 | Buy | $9.60 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 75.50 | Sell |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 23.93 | Neutral |
| Williams %R (14) | -53.33 | Info |
| MACD (12,26,9) | -0.22 | Sell |
| ROC (12) | 0.22 | Buy |
| Bollinger %B (20,2) | 0.58 | Neutral |
| Stochastic %K (14) | 46.67 | Neutral |
| TRIX (15) | 1.54 | Buy |
| Awesome (5,34) | 1.59 | Buy |
| Ultimate (7,14,28) | 49.16 | Neutral |
| Momentum (10) | 0.07 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 13.41 | Sell |
| ADX (14) | 51.36 | Buy |
| ATR (14) | 0.16 | Info |
30-day price action and near-term indicators:
The 30-day range is $11.21 to $16.10.
RSI14 is 80, indicating overbought conditions. SMA50 is $9.71 and SMA200 is $8.72.
Support is at $8.54 and resistance at $13.46.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.70 | $13.38 | $17.05 | 0% | Neutral | |
| $11.57 | $14.51 | $19.25 | +8% | Neutral | |
| $12.56 | $16.16 | $22.17 | +21% | Bullish | |
| $12.78 | $16.80 | $23.69 | +26% | Bullish | |
| $14.83 | $19.87 | $28.65 | +48% | Bullish | |
| $17.09 | $23.29 | $34.27 | +74% | Bullish | |
| $18.34 | $25.40 | $38.05 | +90% | Bullish | |
| $19.08 | $26.82 | $40.85 | +100% | Bullish | |
| $18.78 | $26.78 | $41.41 | +100% | Bullish | |
| $19.55 | $28.27 | $44.31 | +111% | Bullish | |
| $29.16 | $44.86 | $74.60 | +235% | Bullish | |
| $43.69 | $74.76 | $135.52 | +459% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.70 | $13.38 | $15.66 | +0.00% |
| June 2026 | $11.33 | $13.29 | $15.94 | -0.71% |
| July 2026 | $11.58 | $13.69 | $16.64 | +3.08% |
| August 2026 | $11.60 | $13.81 | $16.95 | +0.82% |
| September 2026 | $11.27 | $13.47 | $16.67 | -2.42% |
| October 2026 | $11.22 | $13.48 | $16.80 | +0.04% |
| November 2026 | $11.37 | $13.72 | $17.21 | +1.80% |
| December 2026 | $11.16 | $13.52 | $17.05 | -1.48% |
Click any year to see its month-by-month OGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, OGN is projected to trade between $5.70 and $17.05, averaging $13.38 — a potential gain of 0% from today's $13.38. A consolidation phase looks the most probable path here.
Organon & Co.'s 2027 outlook centres on $14.51, within a $11.57 to $19.25 range. That is up +8% on the projected 2026 average. That marks a +8% change versus current levels. Price action looks broadly range-bound.
By 2028, OGN could reach as high as $22.17, with a base case around $16.16 and support toward $12.56 — roughly +21% from $13.38. Buyers look set to stay in control over this stretch.
Expect OGN to range from $12.78 to $23.69 through 2029. The $16.80 average target implies a +26% move from current prices. That is up +4% on the projected 2028 average. Momentum favours further upside here.
The OGN price prediction for 2030 points to an average of $19.87 (low $14.83, high $28.65) — a potential gain of +48% on today's $13.38. Buyers look set to stay in control over this stretch.
In 2031, OGN is projected to trade between $17.09 and $34.27, averaging $23.29 — a potential gain of +74% from today's $13.38. That is up +17% on the projected 2030 average. Momentum favours further upside here.
Organon & Co.'s 2032 outlook centres on $25.40, within a $18.34 to $38.05 range. That is up +9% on the projected 2031 average. That marks a +90% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, OGN could reach as high as $40.85, with a base case around $26.82 and support toward $19.08 — roughly +100% from $13.38. Momentum favours further upside here.
Expect OGN to range from $18.78 to $41.41 through 2034. The $26.78 average target implies a +100% move from current prices. That is 0% versus the projected 2033 average. Buyers look set to stay in control over this stretch.
The OGN price prediction for 2035 points to an average of $28.27 (low $19.55, high $44.31) — a potential gain of +111% on today's $13.38. Momentum favours further upside here.
In 2040, OGN is projected to trade between $29.16 and $74.60, averaging $44.86 — a potential gain of +235% from today's $13.38. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Organon & Co.'s 2050 outlook centres on $74.76, within a $43.69 to $135.52 range. That is up +67% on the projected 2040 average. That marks a +459% change versus current levels. Momentum favours further upside here.
Investing $1,000 in OGN today (≈ 74.738416 OGN) could be worth
$5,587.46
+$4,587.46 (+459%) by 2050 · US Dollar
Based on the average projected OGN price of $74.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in OGNwould be worth at today's price.
$1,000 invested in OGN on May 27, 2025 (≈ 109.409186 OGN) would be worth
$1,463.89
+$463.89 (+46.4%) today · 1.46× · US Dollar
Based on a OGN entry price of $9.14 vs. today's $13.38.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $13.46 | $994.06 | -0.6% |
| 1 month ago | $13.16 | $1,016.72 | +1.7% |
| 3 months ago | $7.23 | $1,850.62 | +85.1% |
| 6 months ago | $7.71 | $1,735.41 | +73.5% |
| 1 year ago | $9.14 | $1,463.89 | +46.4% |
| All time (5.0y) ago | $36 | $371.67 | -62.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our OGN forecast.
Our base-case forecast reaches $27.00 around 2035.
Implied market cap at $27.00: $7.09B
Multi-year outlook and key forecast points:
The 2026 forecast sits at an average of $13.43 with min $5.70 and max $17.13, and a neutral stance with ROI 0.
From 2027 onward, the forecast shows bullish momentum: 2027 avg $14.65 (ROI 9.1), 2028 avg $16.42 (ROI 22.3), 2029 avg $16.92 (ROI 25.9), and 2030 avg $20.42 (ROI 52.1). 2031 avg $24.11 (ROI 79.5), 2032 avg $26.05 (ROI 94), 2033 avg $27.72 (ROI 106.4), 2034 avg $27.57 (ROI 105.3), and 2035 avg $28.93 (ROI 115.4) with bullish sentiment.
The long horizon shows substantial upside: 2040 avg $46.83 (ROI 248.7) and 2050 avg $77.73 (ROI 478.8), both with bullish sentiment.
These figures are estimates and not guarantees; outcomes depend on market conditions and other factors.
Tap a question to reveal the answer.
avg $20.42; min $15.08; max $29.83; ROI 52.1; sentiment BULLISH.
avg $13.43; min $5.70; max $17.13; ROI 0; sentiment NEUTRAL.
The 2040 forecast max is $79.38, which exceeds 50; 2040 avg is $46.83 with ROI 248.7 and sentiment BULLISH.
avg $77.73; min $44.00; max $144.16; ROI 478.8; sentiment BULLISH.
min $11.61; avg $14.65; max $19.60; ROI 9.1; sentiment NEUTRAL.
Organon & Co. Community Discussion
0Share your Organon & Co. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.